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INTRODUCTION:
The proposal centers on developing the principal investigator (PI) into an independent prostate cancer physician-scientist, using as a vehicle this DoD award with specific research Aims to examine the ERG oncoprotein as a target for prostate cancer therapy by using novel transgenic mice. Prostate cancer is the most common cancer diagnosed in men in the United States. It has been estimated that greater than 200,000 new cases of prostate cancer were diagnosed in the United States in 2012 and prostate cancer was responsible for ~30,000 deaths or the second most common cause of cancer deaths in men (1) . Recent efforts to classify distinct molecular subtypes of prostate cancer have led to the novel findings that greater than 50% of prostate cancers possess a chromosomal translocation involving the ETS oncogene family of transcription factors (2, 3) . These ETS translocations result in dysregulated overexpression of the ETS oncogene in prostate cancer cells. The most common ETS family member involved in these translocation events is the v-ets erythroblastosis virus E26 oncogene homolog (ERG). Most molecular targeted therapies in other cancers are notable for their lack of serious side-effects and amazing tolerability. I hypothesized that ERG, the most common ETS oncogene found to be mutated in prostate cancer can serve as an effective molecular therapeutic target for prostate tumors. I planned to show this with novel autochthonous prostate tumor mouse models. I also hypothesized that ERG facilitates tumorigenesis alone or in the context of activated AKT1 by dysregulating proliferation, apoptosis and/or senescence programs in vivo. Demonstrating whether prostate tumors in mouse models are dependent for ERG for tumor survival would be the first proof of principle demonstration of molecularly targeted therapy for spontaneously arising prostate tumors in living animals. Ultimately, this mentored award has the goal of protecting the research time of the PI to allow development of his research program so that he may become a future leader in prostate cancer research.
The original specific aims are below: Specific Aim#1 -Generate and characterize an inducible ERG prostate specific mouse model. Rationale: I have created a novel prostate TET system mouse model and am interested in the effects of ERG expression alone and in combination with AKT1 in the prostate. Study Design: I will validate inducible expression of both ERG and Luc in vivo using real time-RT-PCR (qPCR), BLI of whole living animals and by organ Western analysis in bi-transgenic ARR2PB-tTA/ ERG-tetO-Luc (AE) mice. Specific Aim#2 -Determine if ERG cooperates with AKT1 for prostate tumorigenesis. Rationale: ERG overexpression in vitro suggests that ERG may facilitate tumorigenesis, but ERG transgenic mouse models vary in the severity of their tumor phenotypes alone and with AKT1 co-overexpression. The mechanism for ERG prostate phenotypes alone or in combination with AKT1 overexpression in vivo are unknown. Study Design: Generate ARR2PB-tTA/MPAKT1/ ERG-tetO-Luc (AA1E) tri-transgenic mice and compare to single oncogene mice to genetically analyze cooperation in vivo. Investigate using molecular techniques if ERG modulates proliferation, apoptosis and/or senescence programs in vivo.
Specific Aim#3 -Determine if ERG can serve as an effective molecular therapeutic target for prostate tumors in vivo.
Rationale: Despite the importance that ERG overexpression is believed to play in prostate tumorigenesis, the therapeutic value of targeting ERG on autochthonous prostate tumors has not been tested in vivo. The mechanism for any autochthonous tumor regression or stasis in vivo upon ERG inactivation is unknown. Study Design: Following development of autochthonous prostate tumors in TET regulated mice I will treat mice with doxycycline to simulate targeted treatment against the ERG oncogene. Investigate using molecular techniques if ERG inactivation modulates proliferation, apoptosis and/or senescence programs in autochthonous prostate tumors in vivo.
KEYWORDS:
ERG Prostate cancer Inducible transgenic mouse model
OVERALL PROJECT SUMMARY:
Progress is listed in relation to each specific task in the "Statement of Work" and highlighted by italics for Years [1] [2] [3] [4] and BOLD font for the past year (Year 5).
Task#1 -Generate and characterize an inducible ERG prostate specific mouse model (months [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Numbers of mice surviving weaning and for mating: 65 1a. IACUC and other regulatory approval process for animal work (months [1] [2] [3] [4] . As reported in our Year [1] [2] [3] [4] Progress Reports, we applied for and obtained approval from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center IACUC for the studies described in our DoD grant award (see Appendix for documentation approval). We had to get re-approval of our IACUC protocol this past year (see Appendix)
1a. Mating mice to characterize (months [4] [5] [6] [7] [8] [9] [10] . As reported in our Year [1] [2] [3] [4] Progress Reports, the appropriate single transgene ARR2PB-tTA (A) and ERG-tetO-Luc (E) mice were mated to produce cohorts of (AE) bitransgenic mice. There were no issues with producing the required numbers of AE mice. We stated in the last progress report (Year 4) that we were generating more bitransgenic, Hoxb13-rtTA/ERG-tetO-luc (HE) and tritransgenic animals, Hoxb13-rtTA/MPAKT1/ERG-tetO-luc (HA1E) mice to perform Task #1 and Task #2, respectively. We have characterized these HE mice using as a reporter, functional expression of luc detected with bioluminescence imaging (BLI) and molecular characterization with qPCR and Western for ERG (data not shown; see Table 1B and Table 2B) 
. We did not see robust BLI signal from the HE mice, nor have we observed high level of ERG expression at the mRNA or protein levels (data not shown). This was in contrast to what we observed with a very similar line Twist1-tetO-luc crossed to the prostate specific TET driver Hoxb13-rtTA (4) (see Figure 1 Appendix). Similarly, we have shown that another founder line of ERG-tetO-luc can express luc from other tissue specific drivers such as those that drive expression ubiquitously (see Figure 2 Appendix) or to the liver (data no shown). The possible explanations are that the HE transgenic combination we selected was not compatible or the particular tetO-ERG founder line we used may have undergone silencing which is a well characterized phenomenon in transgenic mice. We switched to a different tetO-ERG founder line and began to generate more bitransgenic, Hoxb13-rtTA/ERG-tetO-luc (HE) and tritransgenic Hoxb13-rtTA/MPAKT1/ERG-tetO-luc (HA1E) mice to perform Task #1 and Task #2, respectively
1b. Collecting tissues from AE mice to characterize ERG expression (months [8] [9] [10] [11] [12] [13] [14] . AE mice will be weaned and placed on water without doxycycline and 5 males for each of the following age time points: 4, 8, 12 and 24 weeks (n=25 mice total, 5 additional for incidentals), will be interrogated using the assays mentioned below in 1d.
As reported in our Year 1-4 Progress Reports, the appropriate numbers of AE bitransgenic mice (n=25) had been placed on drinking water without doxycycline to activate the ERG transgene.
We collected tissues from HE mice with and without doxycycline (Table 1B) . We will proceed with this sub-Task #1b again when we get more animals with a new founder tetO-ERG line (see Task #1a above).
1c. Collecting tissues from AE mice turned OFF to characterize inducible ERG expression (months [8] [9] [10] [11] [12] [13] [14] . 12 week old males will be followed for the OFF time points: 1, 2 and 4 weeks (n=20 mice total, 5 additional for incidentals) and tissues extracted for interrogation using the assays mentioned below in 1d.
As reported in our Year [1] [2] [3] [4] Progress Reports, the appropriate numbers of AE bitransgenic mice have been placed on regular water (n=20) for [4] [5] [6] weeks following weaning to activate the ERG transgene followed by changing to doxycycline drinking water (0.2 mg/ml) changed weekly to inactivate the ERG transgene. We collected tissues from HE mice turned OFF (Table 2B ). We will proceed with this sub-Task #1c again when we get more animals with a new founder tetO-ERG line (see Task #1a above).
1d. Performing experiments on tissues from mice (months [14] [15] [16] [17] . Tissues from 1b and 1c above will be harvested for histology and flash frozen for molecular studies: prostate lobes, other genitourinary (GU) organs, lungs, heart, liver and spleen. These specimens will then be processed for H&E histology and immunohistochemistry (IHC) performed using anti-Myc, anti-FLAG and anti-luciferase antibodies to confirm prostate luminal cell epithelia expression. Whole lobe and organ Western blotting using the same antibodies will also be performed and transcription of ERG confirmed with specimens using qPCR. See Table 1 and 2 below for summary of results. We were able to harvest AE mice as above for all the "ON" time points at least 5 mice: 4, 8, 12 and 24 weeks. Similarly, for the "OFF" time points we have been able to collect tissues from > 5 mice from the 1, 2 and 4 week time points. We do not see robust BLI signal from the HE mice, nor have we observed high level of ERG expression at the mRNA or protein levels (data not shown & Tables 1B and 2B below).
We have performed analysis as summarized below in Table 1A & 2A. The AE mice from the "ON" time points collected have had no abnormalities on gross or H&E examination of their prostates. The other organs in these mice (lungs, heart, liver and spleen) were also normal on necropsy. Similarly, the AE mice from the "ON" and "OFF" time course displayed no pathology on gross or histologic exam of the H&E slides. We have attempted IHC and westerns for protein expression of ERG that is tagged by Myc and FLAG epitope tags, but have not been able to see expression using either approach. We also attempted on a limited scale luc IHC and ERG qPCR with these samples which were similarly negative. We performed some analysis on the HE mice as summarized below in Table 1B & 2B and we do not observe any gross abnormalities in any of the samples. Nor did we observe any expression of ERG by BLI or other molecular techniques.
1e. Analyzing results of experiments on tissues from mice (months [14] [15] [16] [17] . See Table 1 and Table 2 for summary of results and "Conclusions" below for explanation of results. Many of the steps/tasks below are dependent on the steps above and have not been initiated.
Task#2 -Determine if ERG cooperates with AKT1 for prostate tumorigenesis (months . Numbers of mice surviving weaning and for mating: 150 2a. Mating mice for cooperation experiments (months [14] [15] [16] [17] [18] [19] [20] .
We bred Hoxb13-rtTA/MPAKT1/ERG-tetO-Luc (HA1E) mice for Task #2a, but aborted and sacrificed these specific HA1E mice for the reasons as explained above in Task #1d. We have re-initiated the mating required to produce Hoxb13-rtTA/MPAKT1/ERG-tetO-Luc (HA1E) mice using a new founder tetO-ERG line.
2b. Collecting tissues from cooperation experiments (months [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . 2c. Performing experiments on tissues from mice (months [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Tissues from 2b above will be harvested for histology and flash frozen for molecular studies: prostate lobes, other GU organs, lungs, heart, liver and spleen. These specimens will then be processed for H&E histology and IHC performed using anti-Myc, anti-FLAG and anti-luciferase antibodies. Whole lobe and organ Western blotting using the same antibodies will also be performed and transcription of ERG confirmed with specimens using qPCR. IHC for cleaved caspase 3 (CC3) and . Senescence markers such as p15, p16, p21 and p27 will be analyzed by IHC and qPCR. In addition, I will perform senescence associated beta-galactosidase (SA-gal) staining. 2d. Analyzing results of experiments on tissues from mice (months [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] .
Each of the steps/tasks below is dependent on the steps above and has not been initiated.
Task#3 -Determine if ERG can serve as an effective molecular therapeutic target for prostate tumors in vivo (months 34-60) Numbers of mice surviving weaning and for mating: 120 3a. Mating mice for therapeutic experiments (months 34-40). 3b. Collecting tissues from therapeutic experiments mice ON 6-12 months and then OFF 1-6 months (months 40-56). 3c. Performing experiments on tissues from mice (months 42-58). Tissues from 3b above will be harvested for histology and flash frozen for molecular studies: prostate lobes, other GU organs, lungs, heart, liver and spleen. These specimens will then be processed for H&E histology and IHC performed for Myc, FLAG, luciferase, CC3, Ki-67, p15, p16, p21 and p27. Whole lobe and organ Western blotting using the same antibodies will also be performed and transcription of ERG confirmed with specimens using qPCR. In addition, I will perform SA--gal staining. 3d. Analyzing results of experiments on tissues from mice (months 44-60).
KEY RESEARCH ACCOMPLISHMENTS:
Confirmation that our ARR2Pb-tTA mouse line is not robust enough to drive expression of tetOregulated genes in the mouse prostate.
 Characterization of the HE transgenic mouse showed that either the transgene combination used was not compatible or this particular tetO-ERG founder line we used may have undergone silencing which is a well characterized phenomenon in transgenic mice.  Re-initiated breeding for novel bitransgenic, Hoxb13-rtTA/ERG-tetO-Luc (HE) and tritransgenic animals, Hoxb13-rtTA/MPAKT1/ERG-tetO-Luc (HA1E), using the more robust prostate specific driver Hoxb13-rtTA and a new founder tetO-ERG line.
CONCLUSION:
During this fifth and last year of support we have not been able to been able to adhere to the timeline of our "Statement of Work" -Task#2 -Determine if ERG cooperates with AKT1 for prostate tumorigenesis (months or Task#3 -Determine if ERG can serve as an effective molecular therapeutic target for prostate tumors in vivo (months 34-60). We have been previously successful at completing the tasks for Task#1 -Generate and characterize an inducible ERG prostate specific mouse model (months [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , but this characterization of ERG expression from our old prostate inducible mouse model, ARR2PB-tTA, did not demonstrate any detectable prostate specific ERG expression at the protein level using Western or IHC (see Tables 1A & 2A above) .
We had in our Year 2 progress report concluded that the lack of a prostate phenotype despite prostate epithelium specific expression of other tetO reporter lines was due to the low level of expression from the ARR2PB-tTA line and perhaps insufficient for the in vivo experiments described in our proposal.
In Year 3 we attempted to remedy this issue with low prostate specific expression and proposed to restart Task #1 of the project with the new prostate specific TET driver mouse, Hoxb13-rtTA (H) (4), in collaboration with Dr. Charles Bieberich. The Hoxb13-rtTA line allows for much more robust expression of tetO target genes as compared to our original ARR2PB-tTA line (see Figure 1 Appendix).
In Years [3] [4] , the breeding between our tetO-ERG mice and Dr. Bieberich's Hoxb13-rtTA mice had been problematic, but we overcame these issues and were able to proceed with Tasks #1a-c with the Hoxb13-rtTA/ tetO-ERG (HE) mice (see Table 1B & 2B). We also started breeding mice for Task #2a, but aborted and sacrificed these specific HA1E mice for the reasons below.
In this final Year 5, we completed Task #1d with the HE mice and continued with breeding HA1E mice for Task #2 studies. Unfortunately, we did not observe expression with BLI, via qPCR for ERG or Western for ERG in HE mice (see Table 1B & 2B). We have troubleshot this situation and believe the specific HE transgenic mouse combination we used was not compatible or this particular tetO-ERG line we used may have undergone silencing which is a well characterized phenomenon in transgenic mice. We are in the process of breeding with a new founder tetO-ERG line more HE mice (Task #1a) to proceed again with Tasks #1b-d.
Finally, the ultimate goal of this DoD Prostate Cancer Physician Research Training Award (PRTA) was to help develop the PI into an independent prostate cancer researcher. Concurrently during this entire award period and made possible by this DoD award, the PI has made significant strides in promoting his career as an independently funded prostate cancer physician-scientist with national and international recognition.
"So What"
Despite the importance that ERG overexpression is believed to play in prostate tumorigenesis, the therapeutic value of targeting ERG rearrangements has not been tested in vivo. The ability to interrogate using in vivo model systems whether ERG or other oncogenes are good molecular therapeutic targets could provide a huge leap forward for prostate cancer research and treatment of prostate cancer patients. Demonstrating whether prostate tumors in my inducible transgenic mice are dependent for ERG for tumor maintenance would be the first proof of principle demonstration of molecularly targeted therapy for prostate tumors in vivo and we will be able to determine whether molecularly targeted therapy against ERG in the context of activated AKT1 would be an effective therapy for prostate tumors.
The ultimate goal of this DoD PRTA was to develop the PI into an independent prostate cancer researcher. The PI has made significant strides in promoting his career as an independently funded prostate cancer physician-scientist with national and international recognition.
PUBLICATIONS, ABSTRACTS AND PRESENTATIONS:
 During this fifth and last year of support we have not published any manuscripts, abstracts or presented work directly from the Aims proposed in this DOD PRTA at any venue other than at our own private lab meetings. However, in the spirit of this award protecting the research time of the PI, this has enabled our group to contribute the following reportable outcomes related to prostate cancer research:
Lay Press:
We were awarded a Movember-PCF Challenge grant to test a novel radiation and immunotherapy combination in oligometastatic prostate cancer patients. We were noticed for a donation to our prostate cancer research efforts by a local philanthropic group. 4. http://www.severnaparkvoice.com/community/local-ravens-fans-combine-passion-football-andcharity
Coverage of a collaborative study where we developed a novel small animal optical imaging platform for preclinical research. 5. http://medicalphysicsweb.org/cws/article/research/64139
